Peptide Stack Analyzer Tool Peptide Directory Peptide Discussion Forum Peptide Tools: Stacker & Calculators Trusted Vendors + Vendor Red Flags
Labels

AOD-9604 Peptide Explained: Fat Loss, Metabolism, Clinical Results & What Actually Works

AOD-9604

AOD-9604 is a modified fragment of human growth hormone designed specifically to target fat metabolism. Unlike full growth hormone, it isolates the fat-burning portion of the molecule—allowing it to stimulate fat breakdown without affecting blood sugar, IGF-1, or tissue growth. This makes it one of the most targeted peptides studied for body fat reduction and metabolic support.

In This Breakdown
What Is AOD-9604? How AOD-9604 Works Potential Benefits What to Expect / Including Timeline Stacking Considerations / Best Stack Comparison Compounds Myth vs Reality Side Effects & Considerations Limitations of Research AOD-9604 Research-Use Protocol Human Clinical Research vs. Research-Use Dosing How to Use AOD-9604 (Research-Use Context) Cycle Length & Time Between Cycles Reconstitution & Dose Conversion Solubility & Reconstitution Notes Storage & Stability Supply Planning Monitoring During Use Important Notes Final Takeaway Research & References
What Is AOD-9604?

Quick Summary:

  • Targets fat metabolism directly (not hormonal)
  • Does not increase IGF-1 or affect blood sugar
  • Works best with diet + training (not standalone)
  • Results are gradual, not instant

Type: Growth hormone fragment peptide

Structure: Amino acids 176–191 of HGH

Primary Role: Fat metabolism and lipolysis

Key Feature: Non-anabolic (no IGF-1 stimulation)

AOD-9604 was originally developed as an anti-obesity drug by isolating the exact region of HGH responsible for fat breakdown—while removing the parts responsible for growth and hormonal side effects.

This makes it fundamentally different from traditional growth hormone therapies, which affect multiple systems at once.

Why AOD-9604 Stands Out
  • Targets fat metabolism directly
  • Does not impact IGF-1 or hormone levels
  • Does not cause water retention or tissue growth
  • Non-stimulant (no cardiovascular stress)

Its biggest advantage is specificity—it focuses only on fat metabolism without broader systemic effects.

Who AOD-9604 Is Best For

Best Fit:

  • People stuck in fat-loss plateaus
  • Those wanting fat loss without stimulants
  • Individuals avoiding hormonal peptides
  • Cutting phases or body recomposition

Not Ideal For:

  • Rapid or dramatic weight loss expectations
  • Muscle-building goals
  • Replacing diet and training
AOD-9604 works best as a support tool—not a primary fat-loss driver.
How AOD-9604 Works
Stimulates Lipolysis → Inhibits Fat Storage → Increases Fat Utilization

AOD-9604 works by mimicking the fat-regulating portion of growth hormone, directly influencing how fat cells release and store energy.

What makes it unique:

Unlike full HGH, AOD-9604 does not increase IGF-1 levels and does not significantly impact glucose metabolism, which is why it avoids many of the side effects associated with growth hormone therapy.

In clinical trials, doses up to 1 mg/day showed no significant changes in blood sugar, insulin, or organ growth, with safety profiles comparable to placebo.

Fat Breakdown (Lipolysis)

AOD-9604 stimulates enzymes that break down stored triglycerides into free fatty acids, allowing them to be used for energy.

Fat Storage Inhibition

It also reduces lipogenesis—the formation of new fat—helping prevent further accumulation, especially in calorie surplus conditions.

Metabolic Efficiency

Rather than increasing metabolism like stimulants, AOD-9604 improves how efficiently the body uses stored fat as fuel.

Think of AOD-9604 as a “fat access signal”—it helps your body use stored fat more easily, but it still depends on diet and activity to drive results.
Interesting Research Insight
AOD-9604 was specifically engineered to isolate the fat-burning region of HGH—meaning it keeps the lipolytic effect while removing nearly all growth-related activity.
Potential Benefits

This gap between animal and human data is important—AOD-9604 appears biologically active, but its real-world fat loss effects are typically modest without lifestyle changes.

  • May support gradual fat reduction
  • Targets fat metabolism directly rather than through broad hormone signaling
  • Does not increase IGF-1
  • Does not significantly affect blood sugar in available research
  • May help support body recomposition when paired with diet and training
What to Expect / Including Timeline
What the Research Actually Shows

Human Data:

  • Some trials show reductions in body fat, particularly abdominal fat
  • Other studies show no statistically significant weight loss vs placebo

Animal Data:

  • Increased fat breakdown (lipolysis)
  • Reduced fat formation (lipogenesis)
  • Prevention of weight gain on high-fat diets

AOD-9604 is not a rapid weight-loss compound. Effects are typically gradual and depend heavily on overall lifestyle.

Weeks 1–2:
  • Subtle changes in energy utilization
  • No major visual changes
Weeks 3–6:
  • Gradual fat reduction (if diet supports it)
  • Improved consistency in fat loss
6–12 Weeks:
  • More noticeable body composition changes
  • Better fat-loss sustainability

Consistency and lifestyle alignment matter more than dose intensity.

Stacking Considerations / Best Stack
Best Use Context
AOD-9604 is usually best understood as a support peptide for structured fat-loss phases rather than a standalone body-composition driver.
Best Stack Logic
Because AOD-9604 is non-hormonal and direct-fat-metabolism focused, it is typically positioned alongside training, diet, and broader metabolic support rather than used as a replacement for them.
AOD-9604 is best viewed as a supporting tool—not the primary driver of fat loss.
Comparison Compounds

AOD-9604: Direct fat metabolism (non-hormonal)

CJC-1295 / Ipamorelin: Increase growth hormone → indirect fat loss

Tesamorelin: Clinically proven visceral fat reduction via GH pathway

5-Amino-1MQ: Targets cellular metabolism (NNMT pathway)

AOD-9604 = Direct Fat Signal
GH Peptides = Hormonal Fat Loss
Metabolic Peptides = Energy System Optimization

AOD-9604 is best viewed as a supporting tool—not the primary driver of fat loss.

Myth vs Reality
Myth: “It melts fat without effort”
Reality: Fat loss still depends on diet and energy balance
Myth: “It targets belly fat specifically”
Reality: No peptide can spot-reduce fat
Myth: “It replaces exercise”
Reality: Works best when paired with training
Side Effects & Considerations
  • Generally discussed as milder than full HGH because it does not stimulate IGF-1
  • No significant blood sugar, insulin, or organ-growth changes in the clinical data referenced above
  • Supportive rather than transformational effects in real-world fat loss

Because AOD-9604 avoids many traditional growth-hormone-related pathways, it is often discussed as more targeted and lower-risk than broader HGH-based approaches. Even so, expectations should remain realistic.

Limitations of Research

The gap between animal and human data matters. AOD-9604 appears biologically active, but human outcomes are often modest and not always statistically significant versus placebo.

That means the compound may be better understood as a support tool for fat-loss structure rather than a dramatic standalone intervention.

Dosage, Reconstitution & Protocol

AOD-9604 Research-Use Protocol
Important Evidence Distinction:
The 300–500 mcg subcutaneous protocol below reflects dosing commonly discussed in research-use and peptide communities. It was not established by the published human AOD-9604 obesity trials, which used substantially different doses and primarily oral administration.
5 mg Vial + 3.0 mL BAC Water → 1.667 mg/mL → 1 Unit ≈ 16.67 mcg
Example Research-Use Setup
Vial 5 mg
Water 3.0 mL bacteriostatic water
Concentration 1.667 mg/mL
Conversion 1 unit ≈ 16.67 mcg
Weeks 1–4
Starting Research-Use Range
Dose 300 mcg daily
Units ≈ 18 units
Volume ≈ 0.18 mL
Frequency Once daily
Weeks 5–12
Higher Research-Use Range
Dose 500 mcg daily
Units ≈ 30 units
Volume ≈ 0.30 mL
Frequency Once daily
Research-Use Schedule
Commonly Discussed Timing Morning / fasted
Research-Use Route Subcutaneous
Commonly Discussed Cycle 8–12 weeks
Extended Framework Up to 12–16 weeks
Simple Approach:
The gradual 300 mcg → 500 mcg progression is a commonly discussed research-use framework. It provides a simple way to document dose, syringe volume, and response over time, but it should not be interpreted as a titration schedule established through controlled human clinical trials.
Human Clinical Research vs. Research-Use Dosing
Research-Use SC Framework → Separate From → Human Oral Clinical Development
Published Clinical Context
AOD-9604 underwent human drug-development studies for obesity and weight reduction.
A 12-week randomized study involving approximately 300 adults evaluated oral doses ranging from 1 mg to 30 mg daily, reporting a non-linear dose-response with the largest reported weight-loss signal in the 1 mg group.
A larger 24-week OPTIONS study enrolled 536 adults and evaluated 0.25 mg, 0.5 mg, and 1 mg oral AOD-9604 once daily alongside diet and exercise. This larger trial did not demonstrate a statistically significant weight-loss benefit compared with placebo, and development for obesity was discontinued.
Clinical Dosing vs. Research-Use Dosing
Research-Use SC Range 300–500 mcg daily (commonly discussed)
12-Week Study Oral 1, 5, 10, 20, or 30 mg daily
24-Week OPTIONS Study Oral 0.25, 0.5, or 1 mg daily
Clinical Validation Not established for the SC research-use range
Why this matters:
AOD-9604 has genuine human research history, but published development studies do not establish the modern 300–500 mcg subcutaneous protocol shown elsewhere on this page. Route, formulation, dose, and study purpose were different, so the clinical numbers and the research-use numbers should not be directly compared as though one is simply a higher or lower version of the other.
How to Use AOD-9604 (Research-Use Context)
Common Research-Use Framework
Frequency Once daily
Commonly Discussed Timing Morning / fasted
Cycle Length 8–12 weeks
Optional Extension Up to 12–16 weeks
Research-Use Route Subcutaneous
Timing Context
Morning or fasted administration is commonly discussed in research-use fat-loss protocols.
Human clinical trials have not established that fasted administration improves AOD-9604 efficacy.
No clinically established best time of day exists for subcutaneous AOD-9604.
Route Context
Subcutaneous administration is common in modern research-use discussions.
Published human obesity-development studies primarily evaluated oral AOD-9604, with some earlier intravenous research.
Human clinical evidence for repeated subcutaneous administration remains limited.
Areas of Research-Use Interest
Fat-metabolism and lipolysis research
Body-composition research
Weight-management research
Comparison with full growth-hormone metabolic signaling
Cycle Length & Time Between Cycles
8–12 Week Research-Use Cycle → 4 Week Break → Reassess
Commonly Discussed Research-Use Framework
Typical Cycle 8–12 weeks
Commonly Discussed Break 4 weeks
Extended Framework 12–16 weeks on, followed by 4–6 weeks off
Required Clinical Off-Period Not established
Evidence distinction:
The 8–12 week cycle, 4-week break, and longer 12–16 week framework are commonly discussed in research-use settings. Human clinical trials have not established that these cycle lengths or washout periods are required for AOD-9604 effectiveness or safety.
Ways the Research-Use Framework Is Structured
Option 1 8–12 weeks on, 4 weeks off
Commonly discussed as the standard-length research-use framework.
Option 2 12–16 weeks on, 4–6 weeks off
Represents the longer end of research-use discussions.
Option 3 Defined body-composition research period
Use is sometimes limited to a defined research phase rather than continuous exposure.
Why reassess?
There is no established evidence that AOD-9604 requires a metabolic “reset” or that continuous exposure causes a predictable loss of responsiveness. Break periods should therefore be described as research-use conventions rather than proven biological requirements.
Reconstitution & Dose Conversion (5 mg Vial)
Example Reconstitution Setup
Vial 5 mg
Water 3.0 mL bacteriostatic water
Concentration 1.667 mg/mL
Conversion 1 unit ≈ 16.67 mcg
Conversion Reference
18 units ≈ 300 mcg / 0.18 mL
24 units ≈ 400 mcg / 0.24 mL
30 units ≈ 500 mcg / 0.30 mL
60 units ≈ 1 mg / 0.60 mL
Reconstitution Steps
Draw 3.0 mL bacteriostatic water using a sterile syringe
Add the water slowly down the inside wall of the vial
Gently swirl or roll rather than shaking vigorously
Allow the contents to dissolve completely
Refrigerate after reconstitution
Research Context:
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated subcutaneous AOD-9604 dose.
Solubility & Reconstitution Notes
What Is Known
FDA-reviewed bulk-material information reports AOD-9604 free base as water-soluble up to approximately 2 mg/mL.
The 5 mg / 3.0 mL example on this page produces a concentration of approximately 1.67 mg/mL, which is below that reported bulk-material solubility limit.
AOD-9604 is sensitive to formulation, processing, and environmental conditions that can contribute to aggregation or degradation.
Cloudiness, visible particles, gel-like material, or unexpected precipitation should not automatically be considered normal or safe.
About acetic acid:
Acidified diluents are sometimes discussed in research and compounding contexts for peptides with solubility problems, but a universal “0.1 mL acetic acid + 2.9 mL BAC water” AOD-9604 preparation has not been established through human clinical studies. Formulation should be based on compound-specific manufacturer or pharmacy data rather than a generic online recipe.
Acetic Acid in Research / Laboratory Use
Dilute acetic acid is sometimes used in laboratory peptide work to improve solubility when a peptide does not dissolve adequately in water-based solutions.
AOD-9604 has been specifically discussed in laboratory and research-use settings as a compound that may benefit from acidified solvent conditions when solubility or aggregation becomes a problem.
The purpose of acetic acid in this context is formulation and solubility, not enhancement of AOD-9604's biological effect.
Published human AOD-9604 studies do not establish a standardized acetic-acid reconstitution formula for subcutaneous administration.
Research Finding:
Laboratory peptide methods support the use of dilute acetic acid as a solubility aid for poorly soluble peptides, and AOD-9604 is included in research-use discussions of acidified reconstitution. However, a specific recipe such as 0.1 mL acetic acid plus 2.9 mL bacteriostatic water should be treated as a community or laboratory formulation approach rather than a clinically validated AOD-9604 preparation.
Visual Check
Clear, particle-free solution: Most reassuring visual appearance when the product is expected to form a clear solution.
Unexpected cloudiness or particles: May represent incomplete dissolution, aggregation, contamination, or formulation incompatibility.
Discoloration, visible debris, or major appearance change: Do not assume the preparation remains suitable based on appearance alone.
Storage & Stability
Unmixed Bulk Material
Storage data vary between AOD-9604 free base and AOD-9604 acetate.
FDA-reviewed manufacturer information for AOD-9604 free base reported stability for up to 3 years near −18°C, 1 year at approximately 0–7°C, and 6 months at 7–30°C when appropriately stored.
Manufacturer information for AOD-9604 acetate recommended 2–8°C for shorter-term storage and approximately −20°C for longer-term storage.
Peptide stability depends on formulation, moisture, temperature, impurities, and storage conditions.
After Reconstitution
Refrigeration at 2–8°C is commonly used for research-use preparations.
A 3–4 week use window is commonly discussed in research-use settings but is not a universally established stability period for every AOD-9604 formulation.
Follow formulation-specific stability information supplied by the manufacturer, pharmacy, or testing laboratory whenever available.
Supply Planning (Research-Use Framework)
What this table assumes:
The calculations below are based only on the example 300 mcg daily for Weeks 1–4 followed by 500 mcg daily thereafter. They are supply-math examples, not clinical dosing recommendations.
Supply Planning
8 Weeks ≈ 5 × 5 mg vials
12 Weeks ≈ 8 × 5 mg vials
16 Weeks ≈ 11 × 5 mg vials
Daily Administrations 56–112 across 8–16 weeks
Monitoring During Use
Body weight and body-composition trends
Waist circumference when relevant to the research goal
Injection-site tolerance with subcutaneous research-use administration
Any new or unexpected systemic symptoms
Glucose-related or metabolic laboratory markers when clinically appropriate
IGF-1 context:
Human oral-development studies did not detect statistically significant differences in IGF-1 between AOD-9604 and placebo groups. That finding should not be interpreted as proof that no monitoring is ever appropriate, particularly because modern subcutaneous use has not been adequately characterized in humans.
Important Notes
AOD-9604 is a synthetic growth-hormone-derived peptide fragment developed for obesity and metabolic research.
Human clinical research exists, but the larger obesity-development program did not establish significant weight-loss efficacy.
The 300–500 mcg subcutaneous framework shown on this page is research-use information rather than a clinically validated dosing regimen.
Human oral or intravenous doses should not be directly converted into equivalent subcutaneous doses.
FDA's review found insufficient human information to assess safety and effectiveness of compounded subcutaneous AOD-9604.
Research-use cycle lengths, breaks, fasted timing, and combination protocols should be distinguished from established clinical requirements.
Bottom line:
AOD-9604 has both preclinical metabolic research and genuine human clinical-development history. The useful research-use information can remain on this page, but it should be kept clearly separate from what controlled human trials actually established.
Final Takeaway

AOD-9604 is one of the most targeted fat-metabolism peptides available, designed to improve how the body accesses and uses stored fat.

However, clinical data suggests its effects are supportive—not transformational—making it most effective when combined with diet, training, and a structured fat-loss plan.

Disclaimer: AOD-9604 is not approved by the FDA for medical use. This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before use. Regulatory status varies by country and it is prohibited in competitive sports.
Research & References

Primary Research

Reviews & Supporting Research

  • Reviews describe AOD-9604 as a modified C-terminal fragment of human growth hormone designed to isolate the fat-metabolism effects of GH while avoiding stimulation of the growth hormone receptor, IGF-1 production, and anabolic activity.
  • Although AOD-9604 completed multiple human clinical trials for obesity, the overall program did not demonstrate sufficient weight-loss efficacy to achieve regulatory approval. Preclinical studies consistently demonstrate increased lipolysis and reduced lipogenesis, but translation of these findings into meaningful human fat loss has been limited. More recently, research has explored potential applications in cartilage repair and osteoarthritis, though these investigations remain early-stage.
Research Note: AOD-9604 is one of the more extensively studied metabolic peptides because it progressed through a full pharmaceutical development program, including multiple human obesity trials. Unlike full-length human growth hormone, AOD-9604 was engineered specifically to retain the lipolytic (fat metabolism) region of GH while minimizing effects on IGF-1, blood glucose, and tissue growth. Human studies demonstrated a favorable safety profile and confirmed that it does not significantly stimulate the growth hormone axis. However, the pivotal Phase II obesity trial failed to show clinically meaningful weight loss compared with placebo, preventing regulatory approval. Consequently, while its biological mechanism is well characterized, current evidence does not support AOD-9604 as a proven stand-alone fat-loss therapy, and many claims made online exceed the available clinical evidence.
Peptide Directory →
Email Post
Similar Links:

Comments

Post a Comment